Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination.
Journal
Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278
Informations de publication
Date de publication:
07 May 2024
07 May 2024
Historique:
revised:
04
04
2024
received:
08
03
2024
accepted:
06
04
2024
medline:
7
5
2024
pubmed:
7
5
2024
entrez:
7
5
2024
Statut:
aheadofprint
Résumé
(1) To plot the trajectory of humoral and cellular immune responses to the primary (two-dose) COVID-19 mRNA series and the third/booster dose in B-cell-depleted multiple sclerosis (MS) patients up to 2 years post-vaccination; (2) to identify predictors of immune responses to vaccination; and (3) to assess the impact of intercurrent COVID-19 infections on SARS CoV-2-specific immunity. Sixty ocrelizumab-treated MS patients were enrolled from NYU (New York) and University of Colorado (Anschutz) MS Centers. Samples were collected pre-vaccination, and then 4, 12, 24, and 48 weeks post-primary series, and 4, 12, 24, and 48 weeks post-booster. Binding anti-Spike antibody responses were assessed with multiplex bead-based immunoassay (MBI) and electrochemiluminescence (Elecsys®, Roche Diagnostics), and neutralizing antibody responses with live-virus immunofluorescence-based microneutralization assay. Spike-specific cellular responses were assessed with IFNγ/IL-2 ELISpot (Invitrogen) and, in a subset, by sequencing complementarity determining regions (CDR)-3 within T-cell receptors (Adaptive Biotechnologies). A linear mixed-effect model was used to compare antibody and cytokine levels across time points. Multivariate analyses identified predictors of immune responses. The primary vaccination induced an 11- to 208-fold increase in binding and neutralizing antibody levels and a 3- to 4-fold increase in IFNγ/IL-2 responses, followed by a modest decline in antibody but not cytokine responses. Booster dose induced a further 3- to 5-fold increase in binding antibodies and 4- to 5-fold increase in IFNγ/IL-2, which were maintained for up to 1 year. Infections had a variable impact on immunity. Humoral and cellular benefits of COVID-19 vaccination in B-cell-depleted MS patients were sustained for up to 2 years when booster doses were administered.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Genentech
Informations de copyright
© 2024 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS‐CoV‐2 infection. Nat Med. 2021;27(11):2032‐2040.
Yamamoto S, Mizoue T, Ohmagari N. Analysis of previous infection, vaccinations, and anti‐SARS‐CoV‐2 antibody titers and protection against infection with the SARS‐CoV‐2 omicron BA.5 variant. JAMA Netw Open. 2023;6(3):e233370.
Kreuzberger N, Hirsch C, Andreas M, et al. Immunity after COVID‐19 vaccination in people with higher risk of compromised immune status: a scoping review. Cochrane Database Syst Rev. 2022;8(8):CD015021.
Garjani A, Patel S, Bharkhada D, et al. Impact of mass vaccination on SARS‐CoV‐2 infections among multiple sclerosis patients taking immunomodulatory disease‐modifying therapies in England. Mult Scler Relat Disord. 2022;57:103458.
Schiavetti I, Cordioli C, Stromillo ML, et al. Breakthrough SARS‐CoV‐2 infections in MS patients on disease‐modifying therapies. Mult Scler. 2022;28(13):2106‐2111.
Jakimovski D, Zakalik K, Awan S, et al. COVID‐19 vaccination in multiple sclerosis and inflammatory diseases: effects from disease‐modifying therapy, long‐term seroprevalence and breakthrough infections. Vaccines (Basel). 2022;10(5):695.
Zaloum SA, Wood CH, Tank P, et al. Risk of COVID‐19 in people with multiple sclerosis who are seronegative following vaccination. Mult Scler. 2023;29(8):979‐989.
Smith JB, Gonzales EG, Li BH, Langer‐Gould A. Analysis of rituximab use, time between rituximab and SARS‐CoV‐2 vaccination, and COVID‐19 hospitalization or death in patients with multiple sclerosis. JAMA Netw Open. 2022;5(12):e2248664.
Liu N, Yu W, Sun M, et al. Outcome of COVID‐19 infection in patients with multiple sclerosis who received disease‐modifying therapies: a systematic review and meta‐analysis. J Clin Neurol. 2023;19(4):381‐391.
Weberpals J, Roumpanis S, Barer Y, et al. Clinical outcomes of COVID‐19 in patients with multiple sclerosis treated with ocrelizumab in the pre‐ and post‐SARS‐CoV‐2 vaccination periods: insights from Israel. Mult Scler Relat Disord. 2022;68:104153.
Sormani MP, Inglese M, Schiavetti I, et al. Effect of SARS‐CoV‐2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine. 2021;72:103581.
Petrone L, Sette A, de Vries RD, Goletti D. The importance of measuring SARS‐CoV‐2‐specific T‐cell responses in an ongoing pandemic. Pathogens. 2023;12(7):862.
Sette A, Sidney J, Crotty S. T cell responses to SARS‐CoV‐2. Annu Rev Immunol. 2023;41:343‐373.
Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162‐173.
Kister I, Patskovsky Y, Curtin R, et al. Cellular and humoral immunity to SARS‐CoV‐2 infection in multiple sclerosis patients on ocrelizumab and other disease‐modifying therapies: a multi‐ethnic observational study. Ann Neurol. 2022;91(6):782‐795.
CDC. CDC booster. https://www.cdc.gov/media/releases/2022/s0519‐covid‐booster‐acip.html
Radke EE, Brown SM, Pelzek AJ, et al. Hierarchy of human IgG recognition within the Staphylococcus aureus immunome. Sci Rep. 2018;8(1):13296.
Samanovic MI, Cornelius AR, Gray‐Gaillard SL, et al. Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS‐CoV‐2‐experienced individuals. Sci Transl Med. 2022;14(631):eabi8961.
Elyanow R, Snyder TM, Dalai SC, et al. T cell receptor sequencing identifies prior SARS‐CoV‐2 infection and correlates with neutralizing antibodies and disease severity. JCI Insight. 2022;7(10):e150070.
Snyder TM, Gittelman RM, Klinger M, et al. Magnitude and dynamics of the T‐cell response to SARS‐CoV‐2 infection at both individual and population levels. medRxiv 2020.
Kister I, Curtin R, Pei J, et al. Hybrid and vaccine‐induced immunity against SAR‐CoV‐2 in MS patients on different disease‐modifying therapies. Ann Clin Transl Neurol. 2022;9(10):1643‐1659.
Tsang NNY, So HC, Cowling BJ, Leung GM, Ip DKM. Effectiveness of BNT162b2 and CoronaVac COVID‐19 vaccination against asymptomatic and symptomatic infection of SARS‐CoV‐2 omicron BA.2 in Hong Kong: a prospective cohort study. Lancet Infect Dis. 2023;23(4):421‐434.
Altarawneh HN, Chemaitelly H, Ayoub H, et al. Effect of prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections and severe COVID‐19 in Qatar. medRxiv 2022. doi:10.1101/2022.03.22.22272745
Louapre C, Belin L, Marot S, et al. Three to four mRNA COVID‐19 vaccines in multiple sclerosis patients on immunosuppressive drugs: seroconversion and variant neutralization. Eur J Neurol. 2023;30(9):2781‐2792.
van Dam KPJ, Hogenboom L, Stalman EW, et al. Longitudinal SARS‐CoV‐2 humoral response in MS patients with and without SARS‐CoV‐2 infection prior to vaccination. Front Neurol. 2022;13:1032830.
Sabatino J. Longitudinal adaptive immune responses following sequential SARS‐CoV‐2 vaccinations in MS patients on anti‐CD20 therapies and sphingosine‐1‐phosphate receptor modulators. Mult Scler Relat Disord. 2022;70:104484.
Disanto G, Galante A, Cantu M, et al. Longitudinal postvaccine SARS‐CoV‐2 immunoglobulin G titers, memory B‐cell responses, and risk of COVID‐19 in multiple sclerosis over 1 year. Neurol Neuroimmunol Neuroinflamm. 2022;10(1):e200043.
Petrone L, Tortorella C, Aiello A, et al. Humoral and cellular response to spike of delta SARS‐CoV‐2 variant in vaccinated patients with multiple sclerosis. Front Neurol. 2022;13:881988.
Brill L, Rechtman A, Zveik O, et al. Humoral and T‐cell response to SARS‐CoV‐2 vaccination in patients with multiple sclerosis treated with ocrelizumab. JAMA Neurol. 2021;78(12):1510‐1514.
Tortorella C, Aiello A, Gasperini C, et al. Humoral‐ and T‐cell‐specific immune responses to SARS‐CoV‐2 mRNA vaccination in patients with MS using different disease‐modifying therapies. Neurology. 2022;98(5):e541‐e554.
Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 Covid‐19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84.
Laidlaw BJ, Ellebedy AH. The germinal centre B cell response to SARS‐CoV‐2. Nat Rev Immunol. 2022;22(1):7‐18.
Maglione A, Morra M, Meroni R, Matta M, Clerico M, Rolla S. Humoral response after the booster dose of anti‐SARS‐CoV‐2 vaccine in multiple sclerosis patients treated with high‐efficacy therapies. Mult Scler Relat Disord. 2022;61:103776.
Schiavetti I, Inglese M, Frau J, et al. Antibody response elicited by the SARS‐CoV‐2 vaccine booster in patients with multiple sclerosis: who gains from it? Eur J Neurol. 2023;30(8):2357‐2364.
Achtnichts L, Jakopp B, Oberle M, et al. Humoral immune response after the third SARS‐CoV‐2 mRNA vaccination in CD20 depleted people with multiple sclerosis. Vaccines (Basel). 2021;9(12):1470.
Bajwa HM, Novak F, Nilsson AC, et al. Persistently reduced humoral and sustained cellular immune response from first to third SARS‐CoV‐2 mRNA vaccination in anti‐CD20‐treated multiple sclerosis patients. Mult Scler Relat Disord. 2022;60:103729.
Samanovic MI, Oom AL, Cornelius AR, et al. Vaccine‐acquired SARS‐CoV‐2 immunity versus infection‐acquired immunity: a comparison of three COVID‐19 vaccines. Vaccines (Basel). 2022;10(12):2152.
Branche AR, Rouphael NG, Diemert DJ, et al. Comparison of bivalent and monovalent SARS‐CoV‐2 variant vaccines: the phase 2 randomized open‐label COVAIL trial. Nat Med. 2023;29(9):2334‐2346.
Thompson PW. Efficacy of Covid‐19 vaccines in ethnically diverse population (BAME): a systematic review. Pak J Med Health Sci. 2022;16:922‐925.
Kurupati R, Kossenkov A, Haut L, et al. Race‐related differences in antibody responses to the inactivated influenza vaccine are linked to distinct pre‐vaccination gene expression profiles in blood. Oncotarget. 2016;7(39):62898‐62911.
Haralambieva IH, Salk HM, Lambert ND, et al. Associations between race, sex and immune response variations to rubella vaccination in two independent cohorts. Vaccine. 2014;32(17):1946‐1953.
Saidenberg L, Arbini AA, Silverman GJ, Lotan I, Cutter G, Kister I. Faster B‐cell repletion after anti‐CD20 infusion in black patients compared to white patients with neurologic diseases. Mult Scler Relat Disord. 2022;63:103830.
Rauber S, Korsen M, Huntemann N, et al. Immune response to SARS‐CoV‐2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab. J Neurol Neurosurg Psychiatry. 2022;93:978‐985.
Sabatino JJ Jr, Mittl K, Rowles WM, et al. Multiple sclerosis therapies differentially affect SARS‐CoV‐2 vaccine‐induced antibody and T cell immunity and function. JCI Insight. 2022;7(4):e156978.
Brill L, Raposo C, Rechtman A, et al. Severe acute respiratory syndrome coronavirus 2 third vaccine immune response in multiple sclerosis patients treated with ocrelizumab. Ann Neurol. 2022;91(6):796‐800.
Hvidt AK, Guo H, Andersen R, et al. Long‐term humoral and cellular immunity after primary SARS‐CoV‐2 infection: a 20‐month longitudinal study. BMC Immunol. 2023;24(1):1‐13.
Maglione A, Francese R, Arduino I, et al. Long‐lasting neutralizing antibodies and T cell response after the third dose of mRNA anti‐SARS‐CoV‐2 vaccine in multiple sclerosis. Front Immunol. 2023;14:1205879.
Ruggieri S, Aiello A, Tortorella C, et al. Dynamic evolution of humoral and T‐cell specific immune response to COVID‐19 mRNA vaccine in patients with multiple sclerosis followed until the booster dose. Int J Mol Sci. 2023;24(10):8525.
Aiello A, Coppola A, Ruggieri S, et al. Longitudinal characterisation of B and T‐cell immune responses after the booster dose of COVID‐19 mRNA‐vaccine in people with multiple sclerosis using different disease‐modifying therapies. J Neurol Neurosurg Psychiatry. 2023;94(4):290‐299.
Palomares Cabeza V, Kummer LYL, Wieske L, et al. Longitudinal T‐cell responses after a third SARS‐CoV‐2 vaccination in patients with multiple sclerosis on ocrelizumab or fingolimod. Neurol Neuroimmunol Neuroinflamm. 2022;9(4):e1178.
Madelon N, Heikkila N, Sabater Royo I, et al. Omicron‐specific cytotoxic T‐cell responses after a third dose of mRNA COVID‐19 vaccine among patients with multiple sclerosis treated with ocrelizumab. JAMA Neurol. 2022;79(4):399‐404.
Algu P, Hameed N, DeAngelis T, Stern J, Harel A. Post‐vaccination SARS‐Cov‐2 T‐cell receptor repertoires in patients with multiple sclerosis and related disorders. Mult Scler Relat Disord. 2023;79:104965.
Ford ES, Mayer‐Blackwell K, Jing L, et al. Repeated mRNA vaccination sequentially boosts SARS‐CoV‐2‐specific CD8(+) T cells in persons with previous COVID‐19. Nat Immunol. 2024;25(1):166‐177.
Tarke A, Sidney J, Methot N, et al. Impact of SARS‐CoV‐2 variants on the total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated individuals. Cell Rep Med. 2021;2(7):100355.
Benitez Fuentes JD, Mohamed Mohamed K, de Luna AA, et al. Evidence of exhausted lymphocytes after the third anti‐SARS‐CoV‐2 vaccine dose in cancer patients. Front. Oncologia. 2022;12:975980.
Cai C, Gao Y, Adamo S, et al. SARS‐CoV‐2 vaccination enhances the effector qualities of spike‐specific T cells induced by COVID‐19. Sci Immunol. 2023;8(90):eadh0687.
D'Abramo A, Vita S, Beccacece A, et al. B‐cell‐depleted patients with persistent SARS‐CoV‐2 infection: combination therapy or monotherapy? A real‐world experience. Front Med (Lausanne). 2024;11:1344267.
Wang M, Dehlinger A, Zapata CF, et al. Associations of myeloid cells with cellular and humoral responses following vaccinations in patients with neuroimmunological diseases. Nat Commun. 2023;14(1):7728.